Literature DB >> 11985383

Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions.

Crispin Jenkinson1, Jeremy Hobart, Tarani Chandola, Ray Fitzpatrick, Viv Peto, Michael Swash.   

Abstract

OBJECTIVES: To evaluate response rate, data quality, score reliability and scaling assumptions of the 36 item Short Form Health Survey (SF-36) in a large scale pan European survey of amyotrophic lateral sclerosis (ALS) patients.
DESIGN: A questionnaire based survey of patients diagnosed with ALS across 15 European countries. SAMPLE PATIENTS: presenting at neurological clinics for treatment of their condition were asked to partake in the survey.
RESULTS: 948 patients have been recruited into the survey, from whom responses have been gained in 754 (79.5%). Scores on the eight dimensions of the SF-36 were found to manifest high internal consistency reliability. Items were, in most instances, found to be most highly correlated with their own (corrected) scale score than with other scale scores. However, on two dimensions (role-physical and role-emotional) there was high levels of missing data, together with substantial floor and ceiling effects. The two factor model (of underlying constructs of physical and emotional health) for the SF-36 suggested by the developers was not supported in this patient group. CONCLUSION The SF-36 appears to provide reliable information for this patient group, and for the most part there are high levels of item completeness and good spread of scores. This is not, however, true for the role functioning dimensions. Furthermore, the underlying two factor model for the SF-36 was not supported. The implications for measuring health status in this patient group are discussed.

Entities:  

Mesh:

Year:  2002        PMID: 11985383     DOI: 10.1007/pl00007861

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  11 in total

1.  Psychiatric aspects of amyotrophic lateral sclerosis (ALS).

Authors:  Lorenzo Norris; Guinevere Que; Elham Bayat
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

Review 2.  Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Louisa Ng; Fary Khan; Carolyn A Young; Mary Galea
Journal:  Cochrane Database Syst Rev       Date:  2017-01-10

3.  The Patient Activation Measure: a validation study in a neurological population.

Authors:  Tanya L Packer; George Kephart; Setareh Ghahari; Åsa Audulv; Joan Versnel; Grace Warner
Journal:  Qual Life Res       Date:  2015-01-06       Impact factor: 4.147

4.  Testing the SF-36 in Parkinson's disease. Implications for reporting rating scale data.

Authors:  P Hagell; A L Törnqvist; J Hobart
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

5.  Lithium delays progression of amyotrophic lateral sclerosis.

Authors:  Francesco Fornai; Patrizia Longone; Luisa Cafaro; Olga Kastsiuchenka; Michela Ferrucci; Maria Laura Manca; Gloria Lazzeri; Alida Spalloni; Natascia Bellio; Paola Lenzi; Nicola Modugno; Gabriele Siciliano; Ciro Isidoro; Luigi Murri; Stefano Ruggieri; Antonio Paparelli
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

6.  Validation of the Persian version of the 40-item amyotrophic lateral sclerosis assessment questionnaire.

Authors:  Hosein Shamshiri; Mohammad Reza Eshraghian; Nastaran Ameli; Shahriar Nafissi
Journal:  Iran J Neurol       Date:  2013

7.  Interaction of physical function, quality of life and depression in Amyotrophic lateral sclerosis: characterization of a large patient cohort.

Authors:  Sonja Körner; Katja Kollewe; Susanne Abdulla; Antonia Zapf; Reinhard Dengler; Susanne Petri
Journal:  BMC Neurol       Date:  2015-05-16       Impact factor: 2.474

8.  Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.

Authors:  A E Elia; S Lalli; M R Monsurrò; A Sagnelli; A C Taiello; B Reggiori; V La Bella; G Tedeschi; A Albanese
Journal:  Eur J Neurol       Date:  2015-02-09       Impact factor: 6.089

9.  Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).

Authors:  Marloes Stam; Renske I Wadman; Camiel A Wijngaarde; Bart Bartels; Fay-Lynn Asselman; Louise A M Otto; H Stephan Goedee; Laura E Habets; Janke F de Groot; Marja A G C Schoenmakers; Inge Cuppen; Leonard H van den Berg; W Ludo van der Pol
Journal:  BMJ Open       Date:  2018-07-30       Impact factor: 2.692

10.  Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options.

Authors:  Sonja Körner; Melanie Hendricks; Katja Kollewe; Antonia Zapf; Reinhard Dengler; Vincenzo Silani; Susanne Petri
Journal:  BMC Neurol       Date:  2013-07-12       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.